Metformin Hydrochloride Extended Release Tablets

This product is a hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and can reduce HbAlc by 1% to 2%. Its mechanism of lowering blood sugar is: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization. 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc. 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output. 4. Inhibit intestinal wall cells from taking up glucose. Unlike the action of insulin, this product does not promote fat synthesis, has no obvious hypoglycemic effect on normal people, and generally does not cause hypoglycemia when used alone for type 2 diabetes. <b

The main ingredient of this product is metformin hydrochloride, and its chemical name is 1,1-dimethylbiguanide hydrochloride.

This product is a film-coated tablet, which appears off-white or white after removing the coating.

It is suitable for patients with type 2 diabetes who cannot be well controlled by diet and exercise alone. This product can be used alone or in combination with sulfonylureas or insulin.

Oral administration, during or after meals. The initial dosage is usually once a day, 1 tablet (500 mg) at a time, taken at dinner, and the dosage is adjusted according to blood sugar and urine sugar. The maximum daily dose does not exceed 4 tablets (2000 mg). If once a day, 4 tablets (2000 mg) each time cannot achieve satisfactory therapeutic effects, it can be changed to twice a day, 2 tablets (1000 mg) each time.

Some patients experience gastrointestinal discomfort after taking this product orally, such as nausea, vomiting, abdominal pain, diarrhea, constipation, bloating, indigestion, heartburn, as well as dizziness, headache, flu-like symptoms, abnormal taste, muscle pain, hypotension, palpitations, flushing, chills, chest discomfort, rash, weakness, tiredness, etc.

This product is contraindicated in patients with type 2 diabetes accompanied by ketoacidosis, liver and kidney dysfunction, heart failure, acute myocardial infarction, severe infection and trauma, major surgery, clinical hypotension and hypoxia, a history of lactic acidosis, and those who are allergic to this product.

Precautions for children: The clinical safety and effectiveness of this product in children have not been confirmed. Precautions for pregnancy and lactation: It should not be used by pregnant and lactating women. Precautions for the elderly: Elderly patients (>65 years old) should use it with caution because of weakened renal function and the dosage should be reduced as appropriate.

1. When used in combination with insulin, the hypoglycemic effect is enhanced, and the dosage should be adjusted. 2. This product can enhance the anticoagulant effect of anticoagulants (such as warfarin, etc.), which may cause bleeding tendency. 3. Cimetidine can increase the bioavailability of this product and reduce the renal clearance rate, so the dosage of this product should be reduced. 4. Furosemide increases the serum and whole blood drug concentrations of metformin, but does not change the renal clearance rate of metformin. 5. Nifedipine can increase the absorption of metformin and increase the excretion in urine, but does not affect Tmax and half-life.

Store in a sealed, dry place. The validity period is tentatively 12 months.

0.5 g

24 months.

Suzhou Dawnrays Pharmaceutical Co., Ltd.

• Founded in:

  1995-12-08

• Address:

  No. 268, Minfeng Road, Wuzhong Economic Development Zone, Suzhou

• Tax NO.:

  913205006283933800

• Registered Funds:

  $131.5 million

• Website:

  Log in to view

• Email:

  Log in to view